Certified by Founder Lodge
Immunai
United States - New York, NY
START UP
1 Disclosed Funding Rounds $215,000,000
0 Participating Investments
-
Founded date
2019
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| October, 28 ,2021 | Series B | $215,000,000 |
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Adronite | $5,000,000 | (Feb 20, 2026)
SPRX | $31,000,000 | (Feb 20, 2026)
Vizzia | $35,300,400 | (Feb 20, 2026)
Altesa BioSciences, Inc. | $75,000,000 | (Feb 20, 2026)
NuCube Energy | $13,000,000 | (Feb 20, 2026)
